रिपोर्टों
Alectinib is a 2nd generation TKI developed by Roche. The recommended dose is 600mg taken twice daily. Along with Brigatinib, Alectinib is the usual first line treatment for newly diagnosed ALK-positive lung cancer patients
New
Anyone with lungs can get lung cancer.
ALK Positive Lung Cancer (UK) is a proud member of
ALK Positive UK is committed to producing reliable, accurate and up to date content reflecting the best available research evidence, and best clinical practice. We aim to provide unbiased information free from any commercial conflicts of interest.
The content of this website is for information only and should not be used for the diagnosis or treatment of medical conditions. We are unable to offer specific advice and, if you are worried about any symptoms, please consult your doctor.
ALK पॉज़िटिव यूके इंग्लैंड और वेल्स में एक पंजीकृत चैरिटी है, पंजीकरण संख्या ११८११७१
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recordings or any information storage and retrieval system without permission in writing from ALK Positive Lung Cancer (UK). © All Rights Reserved